Here’s what you should know.
1. CEO Mike Mahoney said high demand for its products is driving revenue, with the company expecting the growth to continue in 2017.
2. The company’s structural heart products project to make more than $300 million in 2017.
The company projects its structural heart products to generate more than $300 million in revenue in 2017.
3. Mr. Mahoney said the company identified and addressed a problem in its European production plant, which produces the Lotus Edge heart valve.
Boston Scientific anticipates filing for FDA approval for the Lotus Edge in the second quarter, with clearance expected by the end of the year.
4. Mr. Mahoney forecasted double digit growth in earnings per share, and analysts are projecting a 14 percent gain.
More articles on improving health:
CMS waives some penalties associated with physician quality reporting system due to ICD-10 code update issues: 4 things to know
Dr. Brian Davis hosts video on The Fundamentals of Endoscopic Surgery exam
These 12 coding changes could affect your anesthesia practice in 2017
